HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ann-Lii Cheng Selected Research

Hepatocellular Carcinoma (Hepatoma)

8/2022Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape.
4/2022Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial.
4/2022Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
1/2022Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
1/2022Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
1/2022Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma.
1/2022Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
1/2022Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.
1/2022Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma.
1/2022Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ann-Lii Cheng Research Topics

Disease

167Neoplasms (Cancer)
10/2022 - 01/2002
153Hepatocellular Carcinoma (Hepatoma)
08/2022 - 01/2003
35Breast Neoplasms (Breast Cancer)
10/2021 - 11/2002
23Lymphoma (Lymphomas)
01/2020 - 06/2003
18Neoplasm Metastasis (Metastasis)
01/2021 - 11/2002
17Colorectal Neoplasms (Colorectal Cancer)
01/2021 - 02/2002
16Marginal Zone B-Cell Lymphoma (MALT Lymphoma)
02/2022 - 08/2005
13Infections
02/2022 - 11/2002
13Liver Neoplasms (Liver Cancer)
12/2020 - 01/2011
13Carcinoma (Carcinomatosis)
04/2013 - 04/2002
12Pancreatic Neoplasms (Pancreatic Cancer)
01/2020 - 03/2006
11Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2020 - 09/2005
10Disease Progression
01/2022 - 09/2005
10Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2016 - 01/2005
9Adenocarcinoma
01/2021 - 08/2005
8Hypertension (High Blood Pressure)
01/2022 - 10/2013
8Fatigue
01/2021 - 01/2009
7Hepatitis
02/2022 - 06/2003
7B-Cell Lymphoma (Lymphoma, B Cell)
04/2019 - 10/2007
7Hepatitis B
01/2018 - 03/2008
7Stomach Neoplasms (Stomach Cancer)
01/2014 - 03/2004
6Colonic Neoplasms (Colon Cancer)
12/2017 - 04/2004
5Esophageal Squamous Cell Carcinoma
10/2022 - 07/2007
5Lung Neoplasms (Lung Cancer)
05/2020 - 03/2010
5Diarrhea
01/2020 - 01/2007
5Brain Neoplasms (Brain Tumor)
11/2018 - 06/2010
5Nausea
05/2018 - 02/2006
5Carcinogenesis
01/2018 - 05/2011
5Adenocarcinoma of Lung
10/2013 - 08/2005
4Fibrosis (Cirrhosis)
04/2022 - 07/2004
4Vomiting
08/2018 - 02/2006
4Ascites
01/2018 - 09/2005
4Neutropenia
10/2017 - 03/2006
4Urinary Bladder Neoplasms (Bladder Cancer)
09/2017 - 10/2009
4Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2015 - 03/2008

Drug/Important Bio-Agent (IBA)

70Sorafenib (BAY 43-9006)FDA Link
04/2022 - 01/2009
27Biomarkers (Surrogate Marker)IBA
10/2022 - 10/2007
25Fluorouracil (Carac)FDA LinkGeneric
06/2019 - 02/2002
24Cisplatin (Platino)FDA LinkGeneric
07/2022 - 04/2002
20Leucovorin (Folinic Acid)FDA Link
06/2019 - 02/2002
18Pharmaceutical PreparationsIBA
08/2018 - 04/2002
17Proteins (Proteins, Gene)FDA Link
01/2021 - 08/2005
16GemcitabineFDA Link
01/2020 - 08/2005
16Phosphotransferases (Kinase)IBA
09/2019 - 09/2009
13Paclitaxel (Taxol)FDA LinkGeneric
07/2022 - 11/2002
13Bevacizumab (Avastin)FDA Link
04/2022 - 05/2009
11Doxorubicin (Adriamycin)FDA LinkGeneric
01/2018 - 07/2003
11DNA (Deoxyribonucleic Acid)IBA
01/2018 - 01/2006
10cabozantinibIBA
04/2022 - 07/2018
10Oxaliplatin (Eloxatin)FDA LinkGeneric
12/2017 - 04/2004
9Immune Checkpoint InhibitorsIBA
08/2022 - 01/2018
9ErbB Receptors (EGF Receptor)IBA
07/2021 - 08/2005
8Aspartate Aminotransferases (Aspartate Transaminase)IBA
01/2022 - 01/2012
8Estrogen ReceptorsIBA
07/2021 - 01/2013
8NF-kappa B (NF-kB)IBA
07/2012 - 04/2002
7atezolizumabIBA
04/2022 - 01/2020
7pembrolizumabIBA
01/2022 - 01/2018
7Biological ProductsIBA
01/2022 - 02/2002
7Bortezomib (Velcade)FDA Link
01/2013 - 08/2008
6Anti-Bacterial Agents (Antibiotics)IBA
02/2022 - 09/2005
6Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
01/2022 - 05/2012
6LigandsIBA
10/2021 - 04/2009
6Cetuximab (Erbitux)FDA Link
01/2021 - 09/2014
6lenvatinibIBA
01/2021 - 01/2018
6Rituximab (Mabthera)FDA Link
01/2020 - 02/2012
6Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
02/2015 - 04/2009
5Thalidomide (Thalomid)FDA Link
02/2022 - 01/2003
5Alanine Transaminase (SGPT)IBA
01/2022 - 07/2012
5Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2021 - 08/2010
5Cytotoxins (Cytolysins)IBA
04/2019 - 07/2004
5AnthracyclinesIBA
08/2018 - 01/2005
5Estrogens (Estrogen)FDA Link
01/2018 - 12/2008
5TamoxifenFDA LinkGeneric
01/2017 - 11/2003
5Methotrexate (Mexate)FDA LinkGeneric
04/2016 - 11/2002
4ParaffinIBA
10/2021 - 09/2004
4Phenobarbital (Luminal)FDA Link
07/2021 - 06/2009
4Monoclonal AntibodiesIBA
01/2021 - 09/2014
4Tyrosine Kinase InhibitorsIBA
01/2021 - 10/2013
4Etoposide (VP 16)FDA LinkGeneric
05/2020 - 04/2015
4Antiviral Agents (Antivirals)IBA
01/2020 - 01/2012
4alpha-Fetoproteins (alpha-Fetoprotein)IBA
01/2020 - 06/2009
4Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
04/2019 - 04/2004
4GlucocorticoidsIBA
08/2018 - 10/2005
4Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
01/2018 - 01/2011
4Interleukin-6 (Interleukin 6)IBA
01/2018 - 07/2004
47-hydroxy-6-methoxyphthalide (MA-1)IBA
02/2017 - 11/2011
4TOR Serine-Threonine KinasesIBA
02/2016 - 12/2010
4tigatuzumabIBA
10/2015 - 05/2011
4TegafurIBA
09/2014 - 07/2010

Therapy/Procedure

102Therapeutics
10/2022 - 11/2003
81Drug Therapy (Chemotherapy)
02/2022 - 01/2002
29Radiotherapy
02/2022 - 02/2007
7Salvage Therapy
01/2020 - 07/2009
7Chemoradiotherapy
08/2018 - 03/2004
6Combination Drug Therapy (Combination Chemotherapy)
01/2020 - 11/2002
5Immunotherapy
10/2021 - 08/2016
5Surgical Instruments (Clip)
07/2016 - 06/2009
4Hepatectomy
01/2022 - 07/2012
4Aftercare (After-Treatment)
01/2018 - 10/2011
4Molecular Targeted Therapy
04/2016 - 08/2010